Eagle Pharmaceuticals Reports Second Quarter 2022 Results

09.08.2022 - •   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share •   Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily ...

Related Keywords

Japan ,United States ,Ukraine ,Debram Hussain ,Lisam Wilson , ,Eagle Pharmaceuticals Inc ,Acacia Pharma Inc ,Eagle Pharmaceuticals ,Site Communications Inc ,Nasdaq ,Investor Relations For Eagle Pharmaceuticals Inc ,Company Annual Report On Form ,Exchange Commission ,Pharmaceuticals Gmb ,Enalare Therapeutics Inc ,Company Quarterly Report On Form ,Acacia Pharma Group ,Pharmaceuticals Gmbh ,Recent Highlights ,Senior Vice President ,Chief Executive Officer ,Months Ended June ,Year Expense ,Acacia Pharma ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Site Communications ,From Concomitant Use With Opioid Analgesics ,